STAR.NS Живые сигналы | Максимизируйте прибыль с Getagraph.com

Live Chart Being Loaded With Signals

Commentary (6 май 2024 @ 13:00):

Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, India, and internationally...

Stats
Объем за сегодня	400 167
Средний объем	463 516
Рыночная капитализация	81.15B
EPS	INR0 ( 2024-01-29 )
Дата следующего отчета о доходах	( INR0 ) 2024-05-23
Last Dividend	INR1.500 ( 2023-08-04 )
Next Dividend	INR0 ( N/A )
P/E	-52.68
ATR14	INR1.825 (0.21%)

Объем Корреляция

Длинно: -0.47 (neutral)

Кратко: -0.80 (strong negative)

Signal:(37.645) Neutral

Strides Pharma Science Корреляция

10 Самые положительные корреляции

10 Самые отрицательные корреляции

Вы знали?

Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).

Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.

Strides Pharma Science Корреляция - Валюта/Сырье

0.54
( weak )

0.09
( neutral )

0.28
( neutral )

0.39
( neutral )

0.19
( neutral )

0.11
( neutral )

Strides Pharma Science Финансовые показатели

Annual	2022
Выручка:	INR36.88B
Валовая прибыль:	INR20.62B (55.89 %)
EPS:	INR-25.63

FY	2022
Выручка:	INR36.88B
Валовая прибыль:	INR20.62B (55.89 %)
EPS:	INR-25.63

FY	2022
Выручка:	INR30.22B
Валовая прибыль:	INR14.39B (47.61 %)
EPS:	INR-52.84

FY	2021
Выручка:	INR32.51B
Валовая прибыль:	INR18.42B (56.67 %)
EPS:	INR29.96

Financial Reports:

No articles found.

Strides Pharma Science Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR1.500 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Strides Pharma Science Dividend Information - No Dividend Player

Dividend Sustainability Score: 0.216 - low (50.00%) | Divividend Growth Potential Score: 1.260 - No dividend expected

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	INR1.500	2010-05-21
Last Dividend	INR1.500	2023-08-04
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	16	--
Total Paid Out	INR651.50	--
Avg. Dividend % Per Year	0.19%	--
Score	0.96	--
Div. Sustainability Score	0.216
Div.Growth Potential Score	1.260
Div. Directional Score	0.738	--

Next Divdend (Est)
(2024-05-08)

INR0 Estimate 3.16 %

Dividend Stability

0.25 Very Poor

Dividend Score

0.96

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2010	INR0	0.00%
2011	INR0	0.00%
2012	INR0	0.00%
2013	INR0	0.00%
2014	INR0	0.00%
2015	INR0	0.00%
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR2.00	0.36%
2019	INR15.00	3.22%
2020	INR2.00	0.55%
2021	INR2.50	0.28%
2022	INR0	0.00%
2023	INR1.500	0.42%
2024	INR0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
ROHLTD.NS	Dividend Junior	2023-09-15	Sporadic	19	0.20%
LAURUSLABS.NS	Dividend Knight	2023-05-10	Semi-Annually	8	0.35%
FOSECOIND.NS	Dividend Knight	2023-05-17	Annually	22	0.68%
APOLLO.NS	Dividend Junior	2023-09-22	Annually	7	0.79%
TCI.NS	Dividend Junior	2023-07-25	Semi-Annually	23	0.70%
OBEROIRLTY.NS	Dividend Junior	2023-06-21	Sporadic	14	0.19%
INFOBEAN.NS	Dividend Junior	2023-07-21	Annually	7	0.37%
CONCOR.NS	Dividend Knight	2023-09-18	Semi-Annually	23	0.89%
SCI.NS	Dividend Junior	2023-09-01	Sporadic	22	0.25%
MALLCOM.NS	Dividend Junior	2023-09-04	Annually	3	0.20%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-0.0259	1.500	-0.519	-0.778	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	-0.0487	1.500	-1.652	-2.48	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	1.132	1.000	-0.692	-0.692	[3 - 30]
operatingCashFlowPerShareTTM	37.52	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	37.52	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.589	1.000	3.52	3.52	[0.2 - 0.8]
operatingProfitMarginTTM	0.0901	1.000	-0.198	-0.198	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				0.216

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-78.48	1.000	-8.03	0	[1 - 100]
returnOnEquityTTM	-0.0487	2.50	-1.062	-2.48	[0.1 - 1.5]
freeCashFlowPerShareTTM	37.52	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	0.170	1.500	5.74	0	[0 - 0.4]
operatingCashFlowPerShareTTM	37.52	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0	1.500	-3.33	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0868	1.000	-0.330	0	[0.1 - 0.5]
Total Score				1.260

Strides Pharma Science

Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, India, and internationally. It operates through two segments, Pharmaceutical and Biopharmaceutical. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, powders, solids, ointments, and creams. It also develops branded generics products for the treatment of chronic therapies, including women's health, central nervous system, cardiovascular, diabetes, dermatology, and probiotics under the Renerve, Unibrol, Combiart, Duotab, and Vitafer brands; and anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for institutional business. The company was formerly known as Strides Shasun Limited and changed its name to Strides Pharma Science Limited in July 2018. Strides Pharma Science Limited was incorporated in 1990 and is headquartered in Bengaluru, India.